Physician profile
Ruby Ann Lopez
NPI 1811481872
$1,460.35
in general payments reported to CMS, 2019-2025
14 companies · $614 in 2025
The $614 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $168 · 2022: $115 · 2023: $161 · 2024: $402 · 2025: $614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,176.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $257.07 | 2024-2025 | Impella |
| Teva Pharmaceuticals USA, INC. | $254.23 | 2023-2025 | Austedo Xr, Austedo Xr, Austedo |
| Otsuka America Pharmaceutical, INC. | $198.13 | 2024-2025 | Rexulti |
| Boston Scientific Corporation | $141.57 | 2025 | Watchman Flx |
| Aurinia Pharma U.S., INC. | $125.02 | 2024 | Lupkynis |
| Paratek Pharmaceuticals, INC. | $122.23 | 2021 | |
| Kyowa Kirin, INC. | $120.54 | 2024 | |
| Abbvie INC. | $56.91 | 2022 | |
| Lilly USA, LLC | $39.76 | 2022-2023 | Trulicity |
| Alpha Cognition USA, INC. | $37.34 | 2025 | Zunveyl |
| Heron Therapeutics, INC. | $37.10 | 2022 | |
| Sumitomo Pharma America, INC. | $24.46 | 2023 | Gemtesa |
| Amarin Pharma, INC. | $23.83 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $22.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruby Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.